Table 1.
Baseline characteristics.
| Overall Population (n = 360) | IPTW Population (n = 718) | |||||
|---|---|---|---|---|---|---|
| High Serum Lactate | Low Serum Lactate | p Value | High Serum Lactate | Low Serum Lactate | p Value | |
| (n = 119) | (n = 241) | (n = 358) | (n =360) | |||
| Age | 61.5 ± 13.0 | 59.6 ± 11.4 | 0.180 | 59.8 ± 13.4 | 60.1 ± 11.4 | 0.763 |
| Male | 89 (74.8) | 205 (85.1) | 0.018 | 292 (81.4) | 394 (81.6) | 0.973 |
| Body mass index, kg/m² | 24.2 ± 4.0 | 24.8 ± 3.3 | 0.124 | 24.8 ± 4.3 | 24.6 ± 3.3 | 0.574 |
| Current smoker | 45 (37.8) | 106 (44.0) | 0.265 | 153 (42.8) | 150 (41.7) | 0.832 |
| Hypertension | 61 (51.3) | 104 (43.2) | 0.146 | 165 (46.1) | 166 (46.1) | >0.999 |
| Diabetes mellitus | 44 (37.0) | 51 (21.2) | 0.001 | 98 (27.3) | 97 (27.0) | 0.942 |
| Dyslipidemia | 19 (16.0) | 51 (21.2) | 0.241 | 55 (15.2) | 80 (22.1) | 0.096 |
| History of percutaneous coronary intervention | 13 (10.9) | 17 (7.1) | 0.211 | 30 (8.3) | 33 (9.1) | 0.793 |
| History of cerebrovascular accident | 8 (6.7) | 6 (2.5) | 0.078 | 27 (7.4) | 10 (2.7) | 0.040 |
| Clinical presentation | ||||||
| NSTEMI | 35 (29.4) | 85 (35.3) | 0.267 | 120 (33.5) | 121 (33.5) | >0.999 |
| STEMI | 84 (70.6) | 156 (64.7) | 0.267 | 238 (66.5) | 239 (66.5) | >0.999 |
| Laboratory findings | ||||||
| NT-proBNP, pg/mL | 240.0 (66.4–1098.8) | 186.4 (51.4–862.9) | 0.126 | 198.7 (57.3–849.4) | 196.9 (53.6–926.3) | 0.618 |
| White blood cell, ×103/μL | 15.7 ± 6.5 | 11.5 ± 3.5 | <0.001 | 15.4 ± 6.0 | 11.5 ± 3.5 | <0.001 |
| Hemoglobin, g/dL | 14.0 ± 1.9 | 14.4 ± 1.9 | 0.062 | 14.3 ± 1.9 | 14.3 ± 2.0 | 0.876 |
| Platelet ×103/μL | 237.6 ± 65.6 | 229.4 ± 60.1 | 0.240 | 236.2 ± 60.2 | 231.6 ± 61.3 | 0.472 |
| Peak CK-MB, ng/mL | 143.1 (40.6–293.2) | 88.6 (29.2–214.2) | 0.002 | 148.6 (56.2–287.4) | 90.7 (28.5–214.1) | <0.001 |
| Concomitant medications | ||||||
| Aspirin | 117 (98.3) | 239 (99.2) | 0.602 | 353 (98.6) | 356 (99.0) | 0.729 |
| P2Y12 inhibitor | 117 (98.3) | 237 (98.3) | 1.000 | 352 (98.3) | 354 (98.4) | 0.943 |
| Beta blocker | 104 (87.4) | 216 (89.6) | 0.526 | 313 (87.4) | 325 (90.3) | 0.385 |
| ACE inhibitor or ARB | 93 (78.2) | 193 (80.1) | 0.670 | 283 (79.0) | 287 (79.7) | 0.867 |
| Statin | 112 (94.1) | 228 (94.6) | 0.849 | 339 (94.6) | 342 (95.0) | 0.853 |
Data are presented as n (%), mean ± standard deviation, or median (interquartile range). ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CK-MB = creatine kinase-myocardial band, IPTW = inverse probability of treatment weighting, NT-proBNP = N-terminal prohormone of brain natriuretic peptide, STEMI = ST-segment elevation myocardial infarction, NSTEMI = non-ST-segment elevation myocardial infarction.